Atorvastatin is a synthetic inhibitor of 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitor. It has a longer half life and longer duration of action than that of all other …

A specific, sensitive, and fast method based on high-performance liquid chromatography
coupled to tandem mass spectrometry was developed for the determination of atorvastatin …

A paucity of substantive data from clinical drug trials is available specifically evaluating the
effects of therapy for hypercholesterolemia in African-Americans, even though a substantial …

This study compared the effects of pravastatin and atorvastatin in a direct switch design to
evaluate differential impact of these statins on serum levels of lipids, lipoproteins and …

The underlying disorder in the vast majority of cases of cardiovascular disease is
atherosclerosis, for which low-density lipoprotein cholesterol is recognized as a major risk …

Abstract Background and Objective Patients with diabetes mellitus might be at a higher risk
of HMG-CoA reductase inhibitor (statin)-induced myotoxicity, possibly because of reduced …

Previous studies have shown that simvastatin, a hydroxymethyl glutaryl coenzyme A
reductase inhibitor, reduces plasma cholesterol levels when administered once a day. In the …

To evaluate the effectiveness of pravastatin, a 3-hydroxy, 3-methyl-glutaryl coenzyme A
(HMG-CoA) reductase inhibitor, as a cholesterol-reducing agent in typical general-practice …

Abstract This 6-week, double-blind clinical trial evaluated lipid parameter responses to
different dosages of atorvastatin in patients with primary hypercholesterolemia. Atorvastatin …